Literature DB >> 12910331

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.

Charles Oo1, George Hill, Albert Dorr, Baolian Liu, Samuel Boellner, Penelope Ward.   

Abstract

OBJECTIVE: The prodrug oseltamivir has been shown to be efficacious and safe for the treatment of influenza for patients 1 year of age or older; however, pharmacokinetic information was lacking for children below 5 years of age. This study was conducted to assess the metabolic and excretory capacity of oseltamivir and its active carboxylate metabolite in young children.
METHODS: Twelve healthy children aged 1-5 years received a single oral suspension dose of oseltamivir (45 mg for 3-5 years, 30 mg for 1-2 years). Plasma and urine concentrations of oseltamivir and the carboxylate were determined by means of liquid chromatography/tandem mass spectrometry.
RESULTS: Mean peak plasma concentration and area under the plasma concentration-time curve values normalized to milligram per kilogram oseltamivir dose in the 1- to 2-year group are lower than those in the 3- to 5-year group. Mean body weight normalized oral clearance of oseltamivir and its carboxylate in younger subjects aged 1-2 years (259 ml/min/kg and 12.2 ml/min/kg) were, respectively, 52% and 30% higher than those in older subjects aged 3-5 years (170 ml/min/kg and 9.4 ml/min/kg).
CONCLUSION: The results demonstrate that infants as young as 1 year old can metabolize and excrete oseltamivir efficiently. The data derived from this study provide the starting dose of oseltamivir for further investigation in an efficacy study among influenza-infected infants less than 1 year of age.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12910331     DOI: 10.1007/s00228-003-0639-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

Review 1.  Drug trials in children: problems and the way forward.

Authors:  S Conroy; J McIntyre; I Choonara; T Stephenson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

2.  Influenza and the rates of hospitalization for respiratory disease among infants and young children.

Authors:  H S Izurieta; W W Thompson; P Kramarz; D K Shay; R L Davis; F DeStefano; S Black; H Shinefield; K Fukuda
Journal:  N Engl J Med       Date:  2000-01-27       Impact factor: 91.245

3.  The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.

Authors:  K M Neuzil; B G Mellen; P F Wright; E F Mitchel; M R Griffin
Journal:  N Engl J Med       Date:  2000-01-27       Impact factor: 91.245

Review 4.  Effect of maturation on drug disposition in pediatric patients.

Authors:  C F Stewart; E M Hampton
Journal:  Clin Pharm       Date:  1987-07

5.  Oral oseltamivir treatment of influenza in children.

Authors:  R J Whitley; F G Hayden; K S Reisinger; N Young; R Dutkowski; D Ipe; R G Mills; P Ward
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

6.  Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.

Authors:  H Wiltshire; B Wiltshire; A Citron; T Clarke; C Serpe; D Gray; W Herron
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-08-18

7.  The impact of influenza epidemics on hospitalizations.

Authors:  L Simonsen; K Fukuda; L B Schonberger; N J Cox
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

8.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Authors:  J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

9.  Developmental changes in hepatic esterase activity towards chloramphenicol succinate and its Michaelis-Menten constant of liver, kidney and lung in human.

Authors:  T Yamakawa; S Itoh; S Onishi; K Isobe; A Hosoe; Y Nishimura
Journal:  Dev Pharmacol Ther       Date:  1984

10.  Developmental patterns of renal functional maturation compared in the human neonate.

Authors:  B S Arant
Journal:  J Pediatr       Date:  1978-05       Impact factor: 4.406

View more
  22 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  H1N1 infection: a pediatric nephrologist's perspective.

Authors:  Sidharth Kumar Sethi
Journal:  Clin Exp Nephrol       Date:  2010-04-06       Impact factor: 2.801

3.  Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.

Authors:  Margaux Boehler; Shirin Bruderer; Ivan Ulč; Jasper Dingemanse
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

4.  Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health.

Authors: 
Journal:  Thorax       Date:  2007-01       Impact factor: 9.139

5.  Oseltamivir dosing in premature infants.

Authors:  Christopher McPherson; Barbara Warner; David A Hunstad; Alexis Elward; Edward P Acosta
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

6.  Oseltamivir dosing for influenza infection in premature neonates.

Authors:  Edward P Acosta; Penelope Jester; Peter Gal; John Wimmer; Joni Wade; Richard J Whitley; David W Kimberlin
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

7.  Effects of body size and gender on the population pharmacokinetics of artesunate and its active metabolite dihydroartemisinin in pediatric malaria patients.

Authors:  Carrie A Morris; Beesan Tan; Stephan Duparc; Isabelle Borghini-Fuhrer; Donald Jung; Chang-Sik Shin; Lawrence Fleckenstein
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

8.  Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin.

Authors:  Dongfang Yang; Robin E Pearce; Xiliang Wang; Roger Gaedigk; Yu-Jui Yvonne Wan; Bingfang Yan
Journal:  Biochem Pharmacol       Date:  2008-10-15       Impact factor: 5.858

9.  Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support.

Authors:  Enno D Wildschut; Matthijs de Hoog; Maurice J Ahsman; Dick Tibboel; Albert D M E Osterhaus; Pieter L A Fraaij
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

10.  Safety of oseltamivir compared with the adamantanes in children less than 12 months of age.

Authors:  David W Kimberlin; Marwan Shalabi; Mark J Abzug; David Lang; Richard F Jacobs; Gregory Storch; John S Bradley; Kelly C Wade; Octavio Ramilo; José R Romero; Mark Shelton; Charles Leach; Judith Guzman-Cottrill; Joan Robinson; Nazha Abughali; Janet Englund; Jill Griffin; Penny Jester; Gretchen A Cloud; Richard J Whitley
Journal:  Pediatr Infect Dis J       Date:  2010-03       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.